EUVIMEDEUVIMED entdecken
Crossref

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study

Saqr Alsakarneh iD, Omar Al Ta'ani iD, Razan Aburumman, Inas Mikhail, Jana G Hashash, Francis A Farraye

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Saqr Alsakarneh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Interleukin-17, Inflammatory Bowel Diseases, Psoriasis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IL‐17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL‐17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL‐17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL‐17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticInterleukin-17Inflammatory Bowel DiseasesPsoriasisThalidomideAnti-Inflammatory Agents, Non-SteroidalHumansFemaleMaleMiddle AgedAdultRisk FactorsAgedAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

IL‐17 inhibitorsSecukinumabinflammatory bowel disease

Substanzen

Interleukin-17apremilastThalidomideAnti-Inflammatory Agents, Non-SteroidalIL17A protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Department of Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Saqr Alsakarneh, Omar Al Ta'ani

Zitieren

APA

Alsakarneh, S., Al Ta'ani, O., Aburumman, R., Mikhail, I., Hashash, J. G., & Farraye, F. A. (2025). Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70139

Vancouver

Alsakarneh S, Al Ta'ani O, Aburumman R, Mikhail I, Hashash JG, Farraye FA. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70139

BibTeX
@article{Alsakarneh2025,
  author = {Alsakarneh, Saqr and Al Ta'ani, Omar and Aburumman, Razan and Mikhail, Inas and Hashash, Jana G and Farraye, Francis A},
  title = {Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70139}
}
Kostenlos starten →